10-K: Strata Critical Medical Reports Strong Revenue Growth, Strategic Shift

Strata Critical Medical, Inc. reported a significant increase in revenue and gross profit for 2025, driven by its focused medical logistics and clinical services strategy following the divestiture of its Passenger business.

Summary

• Strata Critical Medical, Inc. (formerly Blade Air Mobility, Inc.) has fully transitioned to a time-critical logistics and medical services provider for the U.S. healthcare industry.
• Total revenue increased by $50.3 million, or 34.3%, from $146.8 million in 2024 to $197.1 million in 2025.
• Logistics segment revenue grew by 20.4% to $176.8 million in 2025, driven by increased flight hours, ground transportation, and revenue per trip, including new major contracted clients.
• The Clinical segment, established through the acquisition of Keystone Perfusion Services, LLC in mid-September 2025, generated $20.3 million in revenue in 2025.
• Gross profit increased by 39.0% to $41.1 million in 2025 from $29.6 million in 2024, with gross margin improving from 20% to 21%.
• Adjusted EBITDA from continuing operations improved significantly by $10.3 million, reaching $14.1 million in 2025 compared to $3.8 million in 2024.
• Net income from discontinued operations was $61.4 million in 2025, primarily due to a $57.0 million gain on the sale of the Passenger business.
• The company reported a net income of $41.3 million in 2025, a substantial improvement from a net loss of $27.3 million in 2024.
• Cash and cash equivalents stood at $31.0 million and short-term investments at $30.3 million as of December 31, 2025, totaling $61.2 million in liquidity.
• A secured asset-based revolving credit facility (ABL Facility) of up to $30.0 million was entered into in January 2026, with an accordion feature for an additional $20.0 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, reflecting successful strategic execution in divesting the Passenger business and rapidly growing the core medical logistics and clinical services segments, leading to significant financial improvements and a solid liquidity position.

Positives

• Total revenue increased by 34.3% year-over-year to $197.1 million in 2025, demonstrating strong growth in its focused medical business.
• Logistics revenue grew by 20.4% to $176.8 million, indicating successful expansion with existing and new clients.
• The new Clinical segment, established through the Keystone acquisition, contributed $20.3 million in revenue in just over three months of operation.
• Gross profit increased by 39.0% to $41.1 million, and the gross margin improved from 20% to 21%, partly due to operational leverage in ground services and the higher margin of the Clinical segment.
• Adjusted EBITDA from continuing operations saw a substantial improvement of 274%, rising to $14.1 million in 2025 from $3.8 million in 2024.
• The divestiture of the Passenger business resulted in a significant net income from discontinued operations of $61.4 million, including a $57.0 million gain on disposal.
• The company's liquidity position remains strong with $61.2 million in cash and short-term investments as of December 31, 2025.
• Entry into a new $30.0 million ABL Facility in January 2026 provides additional liquidity and financial flexibility, with an option to increase to $50.0 million.
• The company acquired ten fixed-wing aircraft in 2024 to improve economies of scale, increase uptime, and compete for contracts requiring asset ownership.

Negatives

• Selling, general and administrative expenses increased by 19.7% to $60.9 million in 2025, partly due to higher professional fees from legal settlement costs and M&A transaction costs.
• A $1.7 million impairment charge was recorded in 2025 related to an aircraft's airframe due to a corrosion issue, indicating potential asset management challenges.
• Interest income decreased from $7.2 million in 2024 to $4.2 million in 2025, attributed to lower invested balances.
• A realized loss of $5.2 million was incurred from the sale of Joby Aviation securities received from the Passenger business divestiture.
• The company continues to incur net losses from continuing operations, with a loss of $20.1 million in 2025, although an improvement from $16.2 million in 2024.
• The company has a valuation allowance of $19.2 million against net deferred tax assets, indicating uncertainty about future utilization of tax benefits.
• The company has never declared or paid cash dividends and has no intention to do so in the foreseeable future, which may not appeal to income-focused investors.

Risks

• Continued net losses or failure to achieve or maintain profitability.
• Inability to realize anticipated benefits from strategic transactions, including the Passenger business divestiture and Keystone acquisition.
• Harm to reputation or brand from operational issues, public perception, clinical outcomes, or third-party actions.
• Negative publicity, litigation, claims, or regulatory scrutiny related to clinical services, perfusion staffing, or organ recovery activities.
• Reliance on contractual relationships with transplant centers, hospitals, Organ Procurement Organizations (OPOs), and strategic partners.
• Dependence on the availability and utilization of donor organs and transplant volumes, which are influenced by factors beyond control.
• Insufficient reimbursement or funding for organ transport and related services, potentially reducing demand.
• Risks inherent in organ transportation operations, including delivery failures, operational disruptions, or liability exposure.
• Risks associated with ground transportation operations, including accidents, driver error, and regulatory compliance challenges.
• Advancements in preservation technology or alternative transport methods that could reduce demand for private air services.
• Aviation safety risks, including accidents, incidents, or adverse publicity involving aircraft used in operations.
• Climate change, extreme weather events, or environmental developments affecting operations.
• Terrorist attacks, geopolitical conflict, or security events affecting aviation or healthcare infrastructure.
• Volatility in aircraft fuel availability or cost.
• Ability to obtain additional capital or financing on acceptable terms.
• Restrictions under the Credit Agreement that may limit operational or strategic flexibility.
• Ability to manage growth, operational expansion, and integration activities effectively.
• Insurance market conditions, including increased premiums or reduced coverage availability.
• Dependence on key personnel and ability to attract and retain qualified professionals.
• Employment-related claims, workforce litigation, or labor market challenges.
• Ability to maintain company culture as the company grows.
• Fluctuations in financial results and non-comparability of historical financial statements following discontinued operations.
• Risks associated with purchasing aircraft or evolving from an asset-light model, including maintenance costs and impairment charges.
• Risks associated with directly operating aircraft, including increased regulatory oversight, operational complexity, or liability exposure.
• Reliance on maintaining efficient aircraft utilization to manage costs, operating efficiency, and margins.
• Changes in regulatory frameworks in aviation, healthcare, and transplant environments.
• Reliance on third-party aircraft operators and service providers, including risks of inadequate performance or termination of relationships.
• Availability of sufficient third-party aircraft capacity to meet demand.
• Workforce disruptions, operational interruptions, or financial difficulties affecting third-party operators.
• Reputational or operational risks from illegal, improper, or inappropriate operation of Strata-owned or branded aircraft by third parties.
• Reliance on third-party cloud infrastructure, hosting providers, and other technology vendors.
• Interruptions, defects, failures, or vulnerabilities in technology systems or those of third-party providers.
• Cybersecurity incidents, data breaches, or misuse of artificial intelligence technologies.
• Ability to protect and enforce intellectual property rights.
• Risks associated with the use of open-source software.
• Compliance with privacy, data protection, consumer protection, and security laws.
• Expansion of environmental regulations.
• Ability to remediate any material weaknesses or maintain effective internal controls over financial reporting.
• Ability to maintain effective disclosure controls and procedures.
• Volatility in the market price of securities, potentially leading to loss of investment.
• Warrants may expire worthless if the common stock price does not exceed the exercise price.
• Terms of warrants may be amended adversely to holders.
• Company may redeem unexpired warrants at a disadvantageous time for holders.
• Issuance of additional shares of common stock or other equity securities could dilute ownership interest.
• Provisions in charter and Delaware law may inhibit a takeover, limiting stock price and entrenching management.
• Exclusive forum provisions in the Certificate of Incorporation could limit stockholders' ability to choose a favorable judicial forum.
• Future sales by the company or stockholders could cause the market price to decline.

Future Outlook

The company anticipates sufficient funds to meet current operational needs for at least the next 12 months. Longer-term liquidity will depend on expansion into new markets, customer retention, capital expenditures, and acquisitions. The company expects to continue growing its services in the United States and aims to increase the number of organs successfully transplanted while expanding its medical and logistics services customer base. The company believes new organ preservation technology will benefit its business by increasing organ supply and lowering transplant costs.

Management Comments

• "Stratas mission is to increase the number of organs that are successfully transplanted while leveraging the Companys expertise and resources to provide other medical and logistics services to a broader customer base."
• "We believe that, by working with Strata, industry participants can save money, save more lives and operate more efficiently."
• "We made the decision to invest in a limited number of owned aircraft based in high-volume geographies as we believe direct asset ownership will enable (i) improved economies of scale; (ii) increased uptime, enabling more reliable service and higher asset utilization; and (iii) the ability to compete for certain contracts where asset ownership is preferred or required."
• "We prioritize the use of owned aircraft and dedicated aircraft under CPAs, which provide better economies of scale."
• "Our technology enhances the efficiency and cost-effectiveness of our service offerings, further strengthening our position in the organ transportation industry."
• "We have responded to customer demand by introducing new services through our acquisition of Keystone, which launched our Clinical segment and enabled us to provide surgical recovery, NRP and other related services as part of an end-to-end offering."
• "We have also added new offerings organically, such as our TOPS organ placement offering, whereby we assist customers in evaluating the suitability of potential donor organs for transplant."
• "We have historically passed through cost inflation to customers and most logistics contracts with customers automatically pass through any fuel surcharges, but there is no guarantee this will continue in the future."

Industry Context

StockSavvy.ai notes that Strata Critical Medical operates in a highly specialized and regulated segment of the healthcare industry, focusing on time-critical medical logistics and clinical services for organ transplantation. The industry is characterized by a concentrated ecosystem of transplant centers and OPOs, with increasing demand for integrated solutions. Advancements in organ preservation technology are a key trend, potentially increasing organ supply and lowering costs, which could benefit Strata's business model. Competition is evolving, with some preservation device manufacturers now offering bundled logistics and clinical services, creating pressure on traditional providers. Strata's strategy of acquiring clinical capabilities (Keystone) and investing in owned aircraft positions it to offer a more comprehensive, integrated 'one-call solution' to compete effectively against both specialized logistics firms and vertically integrated device manufacturers.

Comparison to Industry Standards

• StockSavvy.ai observes that Strata's reported 34.3% revenue growth in 2025 significantly outpaces the general growth rate of the broader healthcare logistics market, which typically sees single-digit percentage increases. This strong performance is particularly notable given the specialized and highly regulated nature of organ transport.
• The improvement in gross margin from 20% to 21% suggests effective cost management and pricing power, especially with the integration of Keystone's higher-margin clinical services. This margin profile is competitive within specialized medical services, often exceeding those of general logistics providers.
• The substantial increase in Adjusted EBITDA (274%) indicates strong operational leverage and successful execution of the strategic shift, positioning Strata favorably compared to peers still navigating broader market challenges or less focused business models.
• The acquisition of Keystone Perfusion Services and the investment in owned aircraft demonstrate a strategic move towards vertical integration and asset ownership in high-volume geographies. This contrasts with a purely asset-light model, potentially offering greater control over service quality and cost efficiencies, which could be a competitive advantage against smaller, less integrated logistics providers.
• The company's focus on an 'integrated one-call solution' for donor organ recovery, encompassing air/ground logistics, organ placement, surgical recovery, and preservation, aims to differentiate it from competitors that may offer only a subset of these services. This comprehensive approach aligns with the evolving demands of transplant centers and OPOs seeking streamlined operations.

Management Changes

Corporate Governance

Legal Proceedings

• In February 2024, two putative class action lawsuits (Drulias et al. v. Affeldt, et al.) were filed in the Delaware Court of Chancery relating to the acquisition of Blade Urban Air Mobility, Inc. (Old Blade).
• The consolidated complaints allege breach of fiduciary duty and unjust enrichment against former directors and officers of Experience Investment Corp. (EIC) and Experience Sponsor LLC, and aiding and abetting breach of fiduciary duty against Sponsor.
• The operative complaint claims insufficient disclosure in the proxy statement regarding EIC's cash position, Old Blade's value prospects and risks, and information related to Old Blade's former CEO.
• On December 16, 2025, the parties entered into a Stipulation of Settlement to fully resolve the matter, subject to Court approval. The settlement payment was made in December 2025 into escrow.

Related Party Transactions

• The Private Placement Warrants are held by the Sponsor (Experience Sponsor LLC) or its permitted transferees and are non-redeemable by the company for cash under certain conditions, and exercisable on a cashless basis.
• The former Chief Executive Officer, Robert Wiesenthal, transitioned to Joby Aviation following the Passenger business divestiture, and his outstanding equity awards were modified, with associated compensation costs included in discontinued operations.

Stakeholder Impact

• **Shareholders:** Positive impact from strong revenue and Adjusted EBITDA growth, strategic focus on medical services, and a significant net income driven by the Passenger business divestiture. Potential dilution from future equity issuances and warrant exercises remains a risk. The settlement of the Drulias lawsuit removes a legal overhang.
• **Employees:** The company employed 601 employees as of December 31, 2025, with a focus on attracting and retaining skilled professionals. The divestiture of the Passenger business involved personnel transition to Joby Aviation, potentially creating institutional knowledge gaps. The company's culture is highlighted as a contributor to success.
• **Customers (Transplant Centers, OPOs, Hospitals):** Benefit from an integrated 'one-call solution' for organ recovery, including air/ground logistics, organ placement, surgical recovery, and preservation services. The acquisition of Keystone enhances clinical offerings and aims to provide more efficient and reliable services.
• **Suppliers/Third-Party Operators:** The company relies heavily on third-party aircraft operators and service providers. Guaranteed flight commitments through Capacity Purchase Agreements (CPAs) provide stability for some operators, but increased demand for private jets could lead to higher costs or limited availability.
• **Creditors:** The new ABL Facility provides additional liquidity and is secured by eligible personal property, excluding owned aircraft, which could be seen as a positive for creditors. Restrictive covenants in the Credit Agreement may limit operational flexibility.

Next Steps

• Determine the final adjustment for Keystone's actual 2025 Adjusted EBITDA performance by March 2026.
• Hold the annual meeting of stockholders in 2026.
• Continue to display the Strata logo in black or blue on all aircraft by the end of 2026.
• Assess and evaluate strategies to utilize deferred tax assets and reduce the valuation allowance.
• Manage potential earn-out payments for the Keystone acquisition for the three-year period from 2026 through 2028, contingent on gross profit targets.
• Monitor the vesting of PSUs granted in March 2025 (service period ending December 31, 2027) and August 2025 (performance period ending September 30, 2028).

Key Dates

Recommendation

The company has successfully executed a significant strategic pivot, divesting its non-core Passenger business and focusing entirely on the high-growth, high-impact medical logistics and clinical services sector. The reported 34.3% revenue growth and 274% Adjusted EBITDA increase in continuing operations demonstrate strong momentum and operational leverage in its new core business. The acquisition of Keystone has immediately contributed to revenue and improved gross margins, enhancing the company's integrated service offering. While legal proceedings and ongoing losses from continuing operations are noted, the settlement of the class action lawsuit removes a key uncertainty, and the overall financial trajectory is positive. The new ABL facility provides ample liquidity for future growth. The company is well-positioned in a critical and expanding market, making it an attractive investment for long-term growth.

Keywords

Medical Logistics, Organ Transplant, Healthcare Services, Air Transport, Ground Transport, Organ Procurement, Clinical Services, Perfusion Services, Trinity Medical Solutions, Keystone Perfusion Services, SEC Filing, 10-K, Financial Results, Adjusted EBITDA, Revenue Growth, Acquisition, Divestiture, Corporate Governance, Risk Factors, Cybersecurity